Clinical Trial Title
The FLAIR Study is a phase 3, randomized, double-blind study to evaluate the efficacy and safety of a combination of fluticasone (Fp) and albuterol (ABS) in a single inhaler for use as rescue medication compared to albuterol aloneContact Information
Clinical Trial Protocol Description:
The FLAIR Study is evaluating an investigational drug to see how it works in reducing the severity and frequency of asthma attacks in children, adolescents, and adults. The investigational drug is a combination of 2 commercially approved drugs used separately to treat asthma, administered through a single inhaler.
The minimum time that you will be in the study would be at least 6 months, but it can be up to about 3 years. During this time, you will be asked to attend at least 5 study visits at the research center, once every 3 months throughout the study treatment period. You will continue to take your usual asthma maintenance treatment(s) in addition to the investigational drug inhaler that will be used solely for asthma attacks (rescue or reliever treatment). The investigational drug will be administered using an inhaler device. You will have an equal chance of receiving the investigational drug in a high or low dose, or receiving albuterol sulfate (ABS; also known as salbutamol), which is a common drug used for the rescue treatment of asthma.
Clinical Trial Eligibility Criteria:
In order to participate you must meet the following criteria:
- Are 4 years of age or older.
- Have been diagnosed with asthma for at least 1 year.
- Have had 1 or more severe asthma attacks in the past 12 months and have been treated with systemic corticosteroids.
This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.